Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Colorectal cancer is the third most frequent cancer worldwide. Overall survival rates have improved greatly over the last few years due, at least in part, to the addition of targeted therapies to standard of care chemotherapy. Angiogenesis plays an important role in colorectal cancer, and therapies...
Main Authors: | Helena Verdaguer, Josep Tabernero, Teresa Macarulla |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016635888 |
Similar Items
-
Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
by: Hamid Rezvani, et al.
Published: (2022-01-01) -
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
by: Toshiki Masuishi, et al.
Published: (2023-04-01) -
VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment
by: Annalisa Schirizzi, et al.
Published: (2023-10-01) -
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
by: Nadia Saoudi González, et al.
Published: (2024-01-01) -
Encorafenib plus cetuximab for the treatment of -mutated metastatic colorectal cancer
by: Javier Ros, et al.
Published: (2022-07-01)